Literature DB >> 18574673

Impact of protein kinase CK2 on inhibitor of apoptosis proteins in prostate cancer cells.

Guixia Wang1, Kashif A Ahmad, Nathan H Harris, Khalil Ahmed.   

Abstract

We have previously demonstrated that protein kinase CK2 is a potent suppressor of apoptosis in cells subjected to diverse mediators of apoptosis. The process of apoptosis involves a complex series of molecules localized in various cellular compartments. Among the various proteins that modulate apoptotic activity are inhibitors of apoptosis proteins (IAPs) which are elevated in cancers and have been proposed to block caspase activity. We have examined the impact of CK2 signal on these proteins in prostate cancer cells. Cellular IAPs demonstrate distinct localization and responsiveness to altered CK2 expression or activity in the cytoplasmic and nuclear matrix fractions. Modulation of cellular CK2 by various approaches impacts on cellular IAPs such that inhibition or downregulation of CK2 results in reduction in these proteins. Further, IAPs are also reduced when cells are treated with sub-optimal concentrations of chemical inhibitors of CK2 combined with low or sub-optimal levels of apoptosis-inducing agents (such as etoposide) suggesting that downregulation of CK2 sensitizes cells to induction of apoptosis which may be related to attenuation of IAPs. Decreased IAP protein levels in response to apoptotic agents such as TNFalpha or TRAIL were potently blocked upon forced overexpression of CK2 in cells. Together, our results suggest that one of the modes of CK2-mediated modulation of apoptotic activity is via its impact on cellular IAPs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18574673     DOI: 10.1007/s11010-008-9810-9

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  41 in total

Review 1.  Protein kinase CK2 and its role in cellular proliferation, development and pathology.

Authors:  B Guerra; O G Issinger
Journal:  Electrophoresis       Date:  1999-02       Impact factor: 3.535

2.  Consequences of CK2 signaling to the nuclear matrix.

Authors:  S Yu; H Wang; A Davis; K Ahmed
Journal:  Mol Cell Biochem       Date:  2001-11       Impact factor: 3.396

3.  CK2 inhibits apoptosis and changes its cellular localization following ionizing radiation.

Authors:  Kazuhiko Yamane; Timothy J Kinsella
Journal:  Cancer Res       Date:  2005-05-15       Impact factor: 12.701

4.  Modulation of death receptor-mediated apoptosis by CK2.

Authors:  Guixia Wang; Kashif A Ahmad; Khalil Ahmed
Journal:  Mol Cell Biochem       Date:  2005-06       Impact factor: 3.396

Review 5.  Protein kinase CK2: a challenge to canons.

Authors:  Lorenzo A Pinna
Journal:  J Cell Sci       Date:  2002-10-15       Impact factor: 5.285

6.  Roles of IKK kinases and protein kinase CK2 in activation of nuclear factor-kappaB in breast cancer.

Authors:  R Romieu-Mourez; E Landesman-Bollag; D C Seldin; A M Traish; F Mercurio; G E Sonenshein
Journal:  Cancer Res       Date:  2001-05-01       Impact factor: 12.701

Review 7.  Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2.

Authors:  James S Duncan; David W Litchfield
Journal:  Biochim Biophys Acta       Date:  2007-08-30

8.  Phosphorylation of bid by casein kinases I and II regulates its cleavage by caspase 8.

Authors:  S Desagher; A Osen-Sand; S Montessuit; E Magnenat; F Vilbois; A Hochmann; L Journot; B Antonsson; J C Martinou
Journal:  Mol Cell       Date:  2001-09       Impact factor: 17.970

Review 9.  Targeting CK2 for cancer therapy.

Authors:  Kashif A Ahmad; Guixia Wang; Joel Slaton; Gretchen Unger; Khalil Ahmed
Journal:  Anticancer Drugs       Date:  2005-11       Impact factor: 2.248

Review 10.  Survivin, cancer networks and pathway-directed drug discovery.

Authors:  Dario C Altieri
Journal:  Nat Rev Cancer       Date:  2008-01       Impact factor: 60.716

View more
  23 in total

Review 1.  Emergence of protein kinase CK2 as a key target in cancer therapy.

Authors:  Janeen H Trembley; Zhong Chen; Gretchen Unger; Joel Slaton; Betsy T Kren; Carter Van Waes; Khalil Ahmed
Journal:  Biofactors       Date:  2010 May-Jun       Impact factor: 6.113

2.  Apigenin attenuates insulin-like growth factor-I signaling in an autochthonous mouse prostate cancer model.

Authors:  Sanjeev Shukla; Gregory T MacLennan; Pingfu Fu; Sanjay Gupta
Journal:  Pharm Res       Date:  2011-12-03       Impact factor: 4.200

3.  CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoaceptor domain. Translational and clinical research.

Authors:  Silvio E Perea; Idania Baladron; Yanelda Garcia; Yasser Perera; Adlin Lopez; Jorge L Soriano; Noyde Batista; Aley Palau; Ignacio Hernández; Hernán Farina; Idrian Garcia; Lidia Gonzalez; Jeovanis Gil; Arielis Rodriguez; Margarita Solares; Agueda Santana; Marisol Cruz; Matilde Lopez; Carmen Valenzuela; Osvaldo Reyes; Pedro A López-Saura; Carlos A González; Alina Diaz; Lila Castellanos; Aniel Sanchez; Lazaro Betancourt; Vladimir Besada; Luis J González; Hilda Garay; Roberto Gómez; Daniel E Gómez; Daniel F Alonso; Phillipe Perrin; Jean-Yves Renualt; Hugo Sigman; Luis Herrera; Boris Acevedo
Journal:  Mol Cell Biochem       Date:  2011-07-07       Impact factor: 3.396

4.  CK2 functionally interacts with AKT/PKB to promote the β-catenin-dependent expression of survivin and enhance cell survival.

Authors:  Daniela P Ponce; Roger Yefi; Pablo Cabello; Jose L Maturana; Ignacio Niechi; Eduardo Silva; Mario Galindo; Marcelo Antonelli; Katherine Marcelain; Ricardo Armisen; Julio C Tapia
Journal:  Mol Cell Biochem       Date:  2011-07-07       Impact factor: 3.396

5.  Protein B23/nucleophosmin/numatrin nuclear dynamics in relation to protein kinase CK2 and apoptotic activity in prostate cells.

Authors:  Guixia Wang; Yunqian Pan; Kashif A Ahmad; Khalil Ahmed
Journal:  Biochemistry       Date:  2010-05-11       Impact factor: 3.162

6.  Protein kinase CK2 inhibition induces cell death via early impact on mitochondrial function.

Authors:  Fatima Qaiser; Janeen H Trembley; Betsy T Kren; Jing-Jiang Wu; A Khaliq Naveed; Khalil Ahmed
Journal:  J Cell Biochem       Date:  2014-12       Impact factor: 4.429

7.  Overexpressions of CK2β and XIAP are associated with poor prognosis of patients with cholangiocarcinoma.

Authors:  Fan Zhou; Jiewei Xu; Guoping Ding; Liping Cao
Journal:  Pathol Oncol Res       Date:  2013-07-05       Impact factor: 3.201

Review 8.  Protein kinase CK2 in health and disease: CK2: a key player in cancer biology.

Authors:  J H Trembley; G Wang; G Unger; J Slaton; K Ahmed
Journal:  Cell Mol Life Sci       Date:  2009-06       Impact factor: 9.261

9.  Gene expression and epigenetic discovery screen reveal methylation of SFRP2 in prostate cancer.

Authors:  Antoinette S Perry; Gillian O'Hurley; Omer A Raheem; Kevin Brennan; Simon Wong; Anthony O'Grady; Anne-Marie Kennedy; Laure Marignol; Therese M Murphy; Linda Sullivan; Ciara Barrett; Barbara Loftus; John Thornhill; Stephen M Hewitt; Mark Lawler; Elaine Kay; Thomas Lynch; Donal Hollywood
Journal:  Int J Cancer       Date:  2012-09-28       Impact factor: 7.396

10.  Apigenin inhibits prostate cancer progression in TRAMP mice via targeting PI3K/Akt/FoxO pathway.

Authors:  Sanjeev Shukla; Natarajan Bhaskaran; Melissa A Babcook; Pingfu Fu; Gregory T Maclennan; Sanjay Gupta
Journal:  Carcinogenesis       Date:  2013-09-25       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.